search
Back to results

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder

Primary Purpose

Opiate Dependence, Suicidal Ideation, Depression

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Accelerated intermittent theta-burst stimulation (aiTBS)
Sponsored by
Stanford University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opiate Dependence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Over 18 at the time of screening
  2. Able to read, understand, and provide written, dated informed consent prior to screening. Participants will be deemed likely to comply with study protocol and communicate with study personnel about adverse events and other clinically important information.
  3. Diagnosed with Opiate Use Disorder, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders.
  4. Endorse suicidal ideation (score >2 on the SSI-C).
  5. Not in a current state of mania or psychosis (Young Mania Rating Scale)
  6. In good general health, as ascertained by medical history.
  7. If female, a status of non-childbearing potential or use of an acceptable form of birth control per the following specific criteria:, a. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is post-menopausal with her last menses at least one year prior to screening); or, b. Childbearing potential, and meets the following criteria. Childbearing potential, including women using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent. ii. Negative urinary pregnancy test at screening, confirmed by a negative urinary pregnancy test at randomization prior to receiving study treatment. iii. Willing and able to continuously use one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline.
  8. Clear urine drugs test
  9. Registered with a psychiatrist
  10. On stable psychotropic medication or psychotherapy for at least 6 weeks prior to the study with plans to continue throughout study enrollment.
  11. Failed at least one anti-depressant trial (>/=6 week duration at an effective dose)
  12. Ability to tolerate clinical study procedures.
  13. No contraindications for TMS or MRI

Exclusion Criteria:

  1. Any abnormalities indicated on the MRI e.g. structural neurological condition, more subcortical lesions than would be expected for age, stroke effecting stimulated area or connected areas or any other clinically significant abnormality that might affect safety, study participation, or confound interpretation of study results.
  2. Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear
  3. History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)
  4. Shrapnel or any ferromagnetic item in the head.
  5. Pregnancy
  6. Autism Spectrum disorder
  7. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
  8. Active substance use (<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines
  9. Cognitive impairment (including dementia)
  10. Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation)
  11. Current mania
  12. Current unmanageable psychosis
  13. Showing symptoms of withdrawal from alcohol or benzodiazepines
  14. IQ<70
  15. Movement disorder
  16. Any other indication the PI feels would comprise data.
  17. Motor threshold value which does not enable treatment

Sites / Locations

  • Stanford University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Left DLPFC aiTBS stimulation

ACC aiTBS stimulation

Arm Description

Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.

Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.

Outcomes

Primary Outcome Measures

Change in Beck Scale for Suicidal Ideation (SSI) score
19-item clinician administered assessment to measure the intensity, pervasiveness, and characteristics of suicidal ideation in adults. Scores range from 0-38.

Secondary Outcome Measures

Change in Columbia Suicide Severity Scale (C-SSRS) score
Self-report measure for suicidal ideation
Change in Obsessive compulsive drug-use scale (OCDUS) score
Self-report measure of drug craving. This questionnaire will be adapted to make it specific for opiate use.
Change in Montgomery Asberg Depression Rating Scale (MADRS) score
A 10-item clinician-administered scale, designed to be particularly sensitive to antidepressant treatment effects in patients with major depression. Severity gradations for the MADRS have been proposed: 9-17 = mild depression, 18-34 = moderate depression, and ≥ 35 = severe depression. Scores range from 0-60.
Change in Beck Depression Inventory II (BDI-II) score
The Beck Depression Inventory (BDI-II) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
Change in resting-state functional connectivity.
Resting-state fMRI scans will be conducted before and after the course of aiTBS to examine changes in resting-state functional connectivity.

Full Information

First Posted
January 11, 2019
Last Updated
April 12, 2023
Sponsor
Stanford University
search

1. Study Identification

Unique Protocol Identification Number
NCT03804619
Brief Title
Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder
Official Title
Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 1, 2023 (Anticipated)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to examine whether multiple spaced sessions of intermittent theta-burst transcranial magnetic stimulation (iTBS) induce anti-depressant responses and reduce opiate cravings in adults with opiate use disorder (OUD). Additionally, we hope to identify whether the effectiveness of iTBS is related to changes in functional connectivity between particular brain areas.
Detailed Description
The proposed study aims to investigate the effectiveness of aiTBS applied to either the L-DLPFC or the ACC for reducing SI in individuals with OUD and identify neural functional connectivity changes underlying treatment response. 30 individuals with OUD who endorse suicidal ideation will be recruited. The accelerated iTBS treatment will involve 10 daily sessions of iTBS. Stimulation will be delivered to either the ACC or the L-DLPFC for 5 consecutive days. Suicidal ideation, depressive symptoms and opiate misuse will be measured before and after the 5-day stimulation course. Functional magnetic resonance imaging (fMRI) scans will also be carried out before and after stimulation to examine aiTBS-induced changes in neural functional connectivity. Changes in suicidal ideation, depressive symptoms and opiate misuse will be measured using both clinician-rated and self-report assessments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opiate Dependence, Suicidal Ideation, Depression, Opioid Use, Opioid-Related Disorders, Opioid-use Disorder, Major Depressive Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Open label, two-site randomized trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Left DLPFC aiTBS stimulation
Arm Type
Experimental
Arm Description
Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
Arm Title
ACC aiTBS stimulation
Arm Type
Experimental
Arm Description
Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
Intervention Type
Device
Intervention Name(s)
Accelerated intermittent theta-burst stimulation (aiTBS)
Intervention Description
aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
Primary Outcome Measure Information:
Title
Change in Beck Scale for Suicidal Ideation (SSI) score
Description
19-item clinician administered assessment to measure the intensity, pervasiveness, and characteristics of suicidal ideation in adults. Scores range from 0-38.
Time Frame
After all stimulation sessions have been completed (approximately 48 hours after the final session)
Secondary Outcome Measure Information:
Title
Change in Columbia Suicide Severity Scale (C-SSRS) score
Description
Self-report measure for suicidal ideation
Time Frame
After all stimulation sessions have been completed (approximately 48 hours after the final session)
Title
Change in Obsessive compulsive drug-use scale (OCDUS) score
Description
Self-report measure of drug craving. This questionnaire will be adapted to make it specific for opiate use.
Time Frame
After all stimulation sessions have been completed (approximately 48 hours after the final session)
Title
Change in Montgomery Asberg Depression Rating Scale (MADRS) score
Description
A 10-item clinician-administered scale, designed to be particularly sensitive to antidepressant treatment effects in patients with major depression. Severity gradations for the MADRS have been proposed: 9-17 = mild depression, 18-34 = moderate depression, and ≥ 35 = severe depression. Scores range from 0-60.
Time Frame
After all stimulation sessions have been completed (approximately 48 hours after the final session)
Title
Change in Beck Depression Inventory II (BDI-II) score
Description
The Beck Depression Inventory (BDI-II) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
Time Frame
After all stimulation sessions have been completed (approximately 48 hours after the final session)
Title
Change in resting-state functional connectivity.
Description
Resting-state fMRI scans will be conducted before and after the course of aiTBS to examine changes in resting-state functional connectivity.
Time Frame
After all stimulation sessions have been completed (approximately 48 hours after the final session)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Over 18 at the time of screening Able to read, understand, and provide written, dated informed consent prior to screening. Participants will be deemed likely to comply with study protocol and communicate with study personnel about adverse events and other clinically important information. Diagnosed with Opiate Use Disorder, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders. Endorse suicidal ideation (score >2 on the SSI-C). Not in a current state of mania or psychosis (Young Mania Rating Scale) In good general health, as ascertained by medical history. If female, a status of non-childbearing potential or use of an acceptable form of birth control per the following specific criteria:, a. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is post-menopausal with her last menses at least one year prior to screening); or, b. Childbearing potential, and meets the following criteria. Childbearing potential, including women using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent. ii. Negative urinary pregnancy test at screening, confirmed by a negative urinary pregnancy test at randomization prior to receiving study treatment. iii. Willing and able to continuously use one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline. Clear urine drugs test Registered with a psychiatrist On stable psychotropic medication or psychotherapy for at least 6 weeks prior to the study with plans to continue throughout study enrollment. Failed at least one anti-depressant trial (>/=6 week duration at an effective dose) Ability to tolerate clinical study procedures. No contraindications for TMS or MRI Exclusion Criteria: Any abnormalities indicated on the MRI e.g. structural neurological condition, more subcortical lesions than would be expected for age, stroke effecting stimulated area or connected areas or any other clinically significant abnormality that might affect safety, study participation, or confound interpretation of study results. Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear History of epilepsy/ seizures (including history of withdrawal/ provoked seizures) Shrapnel or any ferromagnetic item in the head. Pregnancy Autism Spectrum disorder Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation. Active substance use (<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines Cognitive impairment (including dementia) Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation) Current mania Current unmanageable psychosis Showing symptoms of withdrawal from alcohol or benzodiazepines IQ<70 Movement disorder Any other indication the PI feels would comprise data. Motor threshold value which does not enable treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Brendan Wong
Phone
650-374-0907
Email
bwong14@stanford.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gregory Sahlem, MD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brendan Wong
Email
bwong14@stanford.edu
First Name & Middle Initial & Last Name & Degree
Gregory Sahlem, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder

We'll reach out to this number within 24 hrs